“
TL;DR
The study found high feasibility with >94% enrollment, retention, and adherence, and hydroxyurea was not associated with myelosuppression.
Blood Advances · 11 authors, 7 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The study found high feasibility with >94% enrollment, retention, and adherence, and hydroxyurea was not associated with myelosuppression.
The primary outcome was feasibility, measured by recruitment, retention, and adherence rates. The study enrolled 110 children, with >94% retention and adherence. Safety was assessed via monitoring for myelosuppression, adverse events, and refeeding syndrome.